查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994246

化療誘發周邊神經神經病變治療市場：2026年至2032年全球市場預測（依治療方法、給藥途徑、患者年齡層、治療時間和最終用戶分類）

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Therapy Duration, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，化療引起的周邊神經病變治療市場價值將達到 10.5 億美元，到 2026 年將成長到 11.3 億美元，到 2032 年將達到 18.8 億美元，複合年成長率為 8.64%。

主要市場統計數據
基準年 2025 10.5億美元
預計年份：2026年 11.3億美元
預測年份 2032 18.8億美元
複合年成長率 (%) 8.64%

權威總結了影響腫瘤學各個領域中 CIPN（化療引起的周圍神經病變）管理的不斷變化的臨床重點、護理路徑和相關人員壓力。

化療引起的周邊神經病變（CIPN）仍然是一個持續存在的臨床挑戰，它不僅影響患者的生活品質，也增加了腫瘤治療路徑的複雜性。隨著腫瘤治療方法的多樣化和生存期的延長，臨床醫生越來越重視在維持抗癌療效的同時減輕神經病變症狀的干涉措施。這種不斷變化的臨床需求促使人們關注兼顧藥物治療、非藥物治療和支持性治療的多方面綜合管理方法。

臨床實踐、創新和關鍵變革的軌跡正在重塑支付方對 CIPN 護理的期望。

近年來，持續性重症監護計畫（CIPN）領域受到多項協同變化的影響，這些變化改變了治療方法的評估、應用和報銷方式。首先，人們越來越重視以病人為中心的終點指標和功能性結局，這使得非藥物療法與傳統藥物療法並存的接受度不斷提高。其次，神經生物學和生物標記發現的進步使得預防和緩解症狀的方法更具針對性，並能夠進行基於風險和機制對受試者進行分層的臨床試驗。第三，在支付方框架內，對可證實的臨床效益和整合到治療路徑中的需求日益成長，這迫使研發人員設計出超越隨機對照試驗的證據包。

對 2025 年美國關稅措施對供應鏈、准入和臨床營運的累積影響進行預測分析。

美國關稅的潛在變化可能會對整個化療誘發周邊神經病變（CIPN）治療生態系統產生連鎖反應，改變供應鏈成本、籌資策略策略和製造地地點。提高藥品活性成分、醫療設備或組件的進口關稅可能會促使製造商和經銷商重新評估其採購、庫存策略和供應商多元化。因此，醫療機構和專科診所可能面臨採購計劃和單位成本的變化，這可能會影響藥物選擇和醫療設備部署計劃。因此，越來越需要製定供應鏈韌性規劃，包括關鍵投入品的地理多元化以及提高對上游生產風險的可見性。

主導細分市場洞察，揭示治療方法選擇模式、首選給藥方法、人口統計優先事項、治療持續時間考量和醫療保健服務環境。

化療誘導周邊神經病變 (CIPN) 的治療方案取決於多種治療方法及其應用的臨床背景。根據治療類型，相關人員會將藥物治療（例如抗驚厥藥、抗憂鬱症和鴉片類藥物）與非藥物療法（例如針灸、物理治療和經皮神經電刺激 (TENS)）進行比較。這種權衡反映了療效、耐受性以及盡量減少對癌症治療干擾的必要性。給藥途徑也會影響臨床決策。口服製劑常用於控制慢性症狀，而當需要全身控制時，則採用包括肌肉注射和靜脈注射在內的腸外給藥療法；此外，還有具有局部緩解作用且安全性良好的外用製劑可供選擇。

區域觀點著重分析醫療基礎設施、政策促進因素以及與 CIPN 管理相關的創新採用模式的差異。

地理環境對化療誘導周邊神經病變 (CIPN) 的管理至關重要，因為不同地區的法規環境、報銷機制和醫療基礎設施存在差異。在美洲，成熟的腫瘤網路、活躍的臨床研究以及支付方以結果為導向的策略，都支持將基於指南的治療方法與醫療設備和數位健康解決方案相結合。而在其他地區，不斷變化的報銷模式和獲得專科醫療服務的機會差異，影響著治療方案的部署模式，因此需要製定切實可行且經濟高效的干涉措施，以便在不同的醫療環境中實施。

企業級策略洞察，重點在於塑造 CIPN 解決方案的競爭定位、合作趨勢和創新重點領域。

在CIPN（壓迫性細胞內疼痛和神經性疼痛）領域營運的公司正採取多種策略來鞏固其市場地位，包括產品組合多元化、臨床合作以及技術驅動的服務模式。成熟的製藥公司通常專注於拓展適應症、最佳化配方或支持療效比較研究，以在神經性疼痛治療​​指南中區分已知藥物。同時，專業的醫療設備開發商和數位醫療公司則優先考慮易用性、遠端監測以及在真實臨床環境中驗證功能性益處的證據。隨著各公司尋求以經濟高效的方式生產並快速交付外用製劑和醫療設備耗材給醫療專業人員，契約製造和供應合作夥伴的重要性日益凸顯。

為臨床領導者、開發人員和商業負責人提供實用建議，以加速CIPN護理的採用並改善患者的治療效果。

優先考慮與真實臨床需求相符的證據，設計包含患者報告結局、功能評估指標以及保險公司和臨床醫生認為具有說服力的可操作終點的研究。同時，投資於整合式醫療模式，將藥物治療、非藥物治療和數位症狀監測相結合，以支持門診和居家環境中的持續照護。制定關鍵原料的多元化籌資策略，與本地製造合作夥伴合作以縮短前置作業時間，並減輕貿易中斷的影響，從而降低供應鏈和政策風險。

一份透明的調查方法概要，解釋瞭如何整合、檢驗和組合證據以支持實際見解。

本研究採用的方法結合了對同儕審查的臨床文獻、監管指南和公開的臨床試驗註冊資訊的系統性回顧，以及對臨床專家、供應鏈專家和醫療政策相關人員的結構化訪談。在整合證據時，我們優先考慮高品質的隨機對照試驗、Meta分析和指南建議，並用真實世界數據和觀察性研究來補充任何不足之處，這些數據和研究突出了實施過程中遇到的挑戰。專家諮詢提供了不同醫療機構中臨床實踐的實際情況、實施障礙和未滿足需求的背景性解釋。

總結整合工作，強調了採取綜合方法來改善患者療效的緊迫性，同時克服了商業性和政策方面的阻力。

化療誘導周邊神經病變 (CIPN) 的挑戰涉及生物學、症狀管理和醫療保健系統設計等多個方面。有效的因應措施需要整合策略，結合可靠的臨床證據、高度靈活的照護模式和穩健的供應鏈。隨著臨床重點轉向以病人為中心的療效和功能維持，相關人員必須協調研發、報銷和實施計劃，以在日常實踐中展現顯著療效。同樣重要的是，製藥公司、醫療設備開發商、臨床醫生和保險公司之間需要持續合作，才能將機制研究的進展轉化為可在所有醫療機構實施的可操作干預措施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：化療誘發周邊神經神經病變（依治療方法分類）

  • 非藥物治療
    • 針刺
    • 物理治療
    • 經皮電神經刺激
  • 藥物治療
    • 抗驚厥藥物
    • 抗憂鬱症
    • 鴉片類藥物

第9章：化療誘發周邊神經病變治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
  • 外用

第10章：依病患年齡層別分類的化療誘發周邊神經病變治療市場

  • 成人
  • 老年人
  • 兒童

第11章：化療引起的周邊神經病變（依治療持續時間分類）

  • 長期治療
  • 短期治療

第12章：化療誘發周邊神經病變治療市場：依最終使用者分類

  • 居家醫療
  • 醫院
  • 專科診所

第13章：化療誘發周邊神經病變治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：化療誘發周邊神經病變治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：化療誘發周邊神經病變治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國化療誘發周邊神經神經病變治療市場

第17章：中國化療誘發周邊神經神經病變治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AlgoTherapeutix
  • Amgen Inc.
  • Array BioPharma Inc. by Pfizer Inc.
  • Artelo Biosciences, Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bexion Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Grunenthal GmbH
  • Heron Therapeutics, Inc.
  • Ipsen Pharma
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Neuralace Medical
  • Novartis AG
  • Regenacy Pharmaceuticals LLC
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Serpin Pharma, LLC
  • Takeda Pharmaceutical Company Limited
  • Veloxis Pharmaceuticals, Inc.
Product Code: MRR-1A1A064C04DA

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.13 billion in 2026, with a CAGR of 8.64%, reaching USD 1.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.13 billion
Forecast Year [2032] USD 1.88 billion
CAGR (%) 8.64%

An authoritative synopsis of the evolving clinical priorities, care pathways, and stakeholder pressures shaping CIPN management across oncology settings

Chemotherapy-induced peripheral neuropathy (CIPN) remains a persistent clinical challenge that affects patient quality of life and can complicate oncology care pathways. As oncology regimens diversify and survivorship grows, clinicians increasingly prioritize interventions that reduce neuropathic symptoms while preserving anticancer efficacy. This evolving clinical imperative has elevated interest in multimodal management approaches that balance pharmacological therapy with non-pharmacological interventions and supportive care strategies.

Consequently, payers, health systems, and specialty clinics are aligning protocols to emphasize symptom relief, functional preservation, and continuity of cancer therapy. These stakeholders are also contending with constrained resources and competing priorities, which makes evidence-backed, cost-effective interventions especially attractive. In parallel, research communities are broadening the investigative lens to include preventive strategies, mechanistic biomarkers, and patient-reported outcome measures that better capture the lived experience of CIPN.

Taken together, the current landscape demands integrated thinking across clinical development, service delivery, and commercial strategy. By focusing on multidisciplinary solutions that are adaptable across care settings, stakeholders can better address unmet needs while managing complexity across regulatory, reimbursement, and supply chain dimensions.

Key transformative shifts reshaping clinical practice, innovation trajectories, and payer expectations in CIPN care

Over recent years the CIPN landscape has been reshaped by several converging shifts that alter how therapies are evaluated, adopted, and reimbursed. First, there is stronger emphasis on patient-centered endpoints and functional outcomes, which has expanded acceptance of non-pharmacological modalities alongside traditional drug therapies. Second, advances in neurobiology and biomarker discovery are informing more targeted approaches to prevention and symptomatic relief, enabling trials that stratify participants by risk and mechanism. Third, payer frameworks are increasingly demanding demonstrable real-world benefit and care pathway integration, prompting developers to design evidence packages that extend beyond randomized controlled trials.

Moreover, digital health tools and remote monitoring technologies have accelerated integration of home-based assessments, facilitating continuous symptom tracking and adaptive management. Meanwhile, growing scrutiny of opioid-based strategies has encouraged diversification toward anticonvulsants, antidepressant agents used for neuropathic pain, topical formulations, and device-based therapies. These combined forces are incentivizing cross-disciplinary partnerships among drug developers, device manufacturers, clinical networks, and health technology vendors, driving a more collaborative innovation model that emphasizes pragmatic, scalable solutions.

Analysis of the projected cumulative effects of prospective United States tariff measures on supply chains, access, and clinical operations in 2025

Potential tariff changes in the United States can reverberate through the CIPN therapy ecosystem by altering supply chain costs, procurement strategies, and manufacturing footprints. An increase in import duties on active pharmaceutical ingredients, medical devices, or component materials would likely prompt manufacturers and distributors to reassess sourcing, inventory strategies, and supplier diversification. In turn, providers and specialty clinics may experience changes in procurement timelines and unit costs that influence formulary decisions and device deployment plans. Consequently, there is a heightened need for supply chain resilience planning that includes geographic diversification of key inputs and greater visibility into upstream manufacturing risks.

At the clinical level, administrative burdens associated with altered customs processes and longer lead times could affect timely availability of topical agents, patches, and device consumables used in outpatient and home care settings. In addition, tariff-driven cost pressures may accelerate shifts toward generics, local manufacturing partnerships, or vertically integrated supply arrangements. From a strategic perspective, stakeholders should evaluate the interplay between trade policy, regulatory approvals, and domestic manufacturing incentives to preserve continuity of care and to mitigate unintended barriers to patient access.

Segmentation-driven insights that illuminate treatment choices, administration preferences, demographic priorities, duration considerations, and care delivery settings

Treatment selection for CIPN is shaped by a spectrum of therapeutic modalities and the clinical contexts in which they are deployed. Based on treatment type, stakeholders weigh pharmacological options such as anticonvulsants, antidepressants, and opioids against non-pharmacological alternatives that include acupuncture, physical therapy, and transcutaneous electrical nerve stimulation; this balancing act reflects efficacy evidence, tolerability, and the need to minimize interference with cancer therapy. Route of administration considerations also influence clinical decision-making, with oral agents frequently used for chronic symptom management, parenteral options employed when systemic control is required including intramuscular and intravenous approaches, and topical formulations offering localized relief with favorable safety profiles.

Patient age group is a critical filter for therapy design and delivery, as adults, geriatric patients, and pediatric populations present distinct risk-benefit profiles, comorbidity burdens, and adherence challenges. Therapy duration further influences care plans, where short-term interventions target acute or transient neuropathic episodes and long-term therapy prioritizes sustained symptomatic control and functional preservation. End-user environments shape implementation feasibility and resource allocation; home care settings favor user-friendly, low-burden interventions that support self-management, hospitals must integrate CIPN protocols into complex oncology workflows, and specialty clinics often deliver multimodal, multidisciplinary care with access to device-based therapies and procedural options.

Understanding these intersecting segmentation dimensions enables more precise pathway design, targeted evidence generation, and tailored commercialization strategies that resonate with clinicians, caregivers, and patients across diverse clinical contexts.

Regional perspectives that highlight differing healthcare infrastructures, policy drivers, and innovation adoption patterns relevant to CIPN management

Geographic context matters deeply for CIPN management, as regions demonstrate distinct regulatory environments, reimbursement mechanisms, and care delivery infrastructures. In the Americas, established oncology networks, robust clinical research activity, and payer emphasis on outcomes have supported integration of guideline-based therapies alongside device and digital health solutions. Elsewhere, evolving reimbursement models and varied access to specialty services shape adoption patterns and demand pragmatic, cost-conscious interventions that can be delivered across diverse care settings.

Within Europe, Middle East & Africa, regulatory harmonization in some markets contrasts with fragmented procurement and variable specialist availability in others, making regionally tailored evidence and pricing strategies essential. In the Asia-Pacific region, rapid capacity expansion in oncology services, growing clinical trial activity, and increasing investment in domestic manufacturing create both opportunities and operational complexities for companies seeking regional scale. Across all regions, differences in clinician training, patient expectations, and health system priorities require adaptive commercialization and partnership approaches to ensure therapies reach appropriate patient populations while aligning with local standards of care.

Strategic company-level insights highlighting competitive positioning, partnership trends, and innovation focus areas shaping CIPN solutions

Companies active in the CIPN domain are pursuing multiple pathways to strengthen their market positions, including portfolio diversification, clinical collaboration, and technology-enabled service models. Established pharmaceutical manufacturers often focus on expanding label indications, optimizing delivery formulations, or supporting comparative effectiveness research to differentiate familiar agents within neuropathic pain guidelines. Specialized device developers and digital health firms emphasize usability, remote monitoring, and evidence generation that demonstrates functional benefits in real-world settings. Contract manufacturers and supply partners are increasingly important as firms seek cost-efficient production and faster time-to-provider for topical formulations and device consumables.

Across the ecosystem, strategic alliances and clinical partnerships are common as stakeholders combine therapeutic expertise with procedural skills and digital capabilities. Intellectual property strategies lean toward formulation patents, device innovations, and data-driven approaches to outcome measurement. Meanwhile, competitive pressures from generics and off-label prescribing drive a focus on value demonstration, patient stratification, and niche positioning that highlights safety, tolerability, and integration into multidisciplinary care pathways.

Actionable recommendations for clinical leaders, developers, and commercial strategists to accelerate adoption and improve patient outcomes in CIPN care

Prioritize evidence that aligns with real-world clinical needs by designing studies that incorporate patient-reported outcomes, functional measures, and pragmatic endpoints that payers and clinicians find compelling. Simultaneously, invest in integrated care models that combine pharmacological therapies with non-pharmacological modalities and digital symptom monitoring to support continuity of care in outpatient and home environments. To mitigate supply chain and policy risk, develop diversified sourcing strategies for critical inputs and engage with regional manufacturing partners to reduce lead times and exposure to trade disruptions.

Engage proactively with payer bodies and clinical guideline committees to ensure that dossiers reflect the full spectrum of clinical value, including safety, quality-of-life impact, and health system efficiencies. Forge interdisciplinary partnerships across oncology, neurology, rehabilitation, and palliative care to accelerate adoption of multimodal protocols and to foster clinician champions. Finally, tailor commercialization strategies to the nuances of regional markets and care settings, emphasizing scalable training programs, implementation support, and outcomes tracking that demonstrate sustained patient benefit.

Transparent research methodology summary describing how evidence was integrated, validated, and synthesized to support actionable insights

The research approach combined systematic review of peer-reviewed clinical literature, regulatory guidance, and publicly available clinical trial registries with structured interviews of clinical experts, supply chain specialists, and health policy stakeholders. Evidence synthesis prioritized high-quality randomized controlled trials, meta-analyses, and guideline recommendations while supplementing gaps with real-world evidence and observational studies that illuminate implementation challenges. Expert consultations provided contextual interpretation of clinical practice realities, adoption barriers, and unmet needs across different care settings.

Data validation included cross-referencing therapeutic mechanisms, administration routes, and standard-of-care practices against clinical guidelines and specialist input to ensure consistency. Where policy or trade scenarios were analyzed, publicly available regulatory notices and trade documentation were reviewed to ground implications in verifiable developments. Finally, insights were iteratively reviewed by multidisciplinary advisors to refine recommendations and to ensure the final narrative supports pragmatic decision-making for clinicians, developers, and commercial teams.

Concluding synthesis that underscores the urgency of integrated approaches to improving patient outcomes while navigating commercial and policy headwinds

CIPN presents a multifaceted challenge that spans biology, symptom management, and health system design. Effective responses require integrated strategies that combine robust clinical evidence, adaptable care models, and resilient supply chains. As clinical priorities shift toward patient-centered outcomes and functional preservation, stakeholders must align development, reimbursement, and implementation plans to demonstrate meaningful benefit in routine practice. Equally important is the sustained collaboration among drug developers, device innovators, clinicians, and payers to translate mechanistic advances into pragmatic interventions that are accessible across care settings.

In summary, the path forward is characterized by opportunity for stakeholders who can generate relevant evidence, design for real-world implementation, and build operational resilience in the face of policy and supply uncertainties. By embracing multidisciplinary approaches and regionally tailored strategies, organizations can make measurable improvements in symptom control, patient quality of life, and continuity of cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Type

  • 8.1. Non-Pharmacological Treatments
    • 8.1.1. Acupuncture
    • 8.1.2. Physical Therapy
    • 8.1.3. Transcutaneous Electrical Nerve Stimulation
  • 8.2. Pharmacological Treatments
    • 8.2.1. Anticonvulsants
    • 8.2.2. Antidepressants
    • 8.2.3. Opioids

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Topical

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Therapy Duration

  • 11.1. Long-Term Therapy
  • 11.2. Short-Term Therapy

12. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by End-User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Chemotherapy Induced Peripheral Neuropathy Treatment Market

17. China Chemotherapy Induced Peripheral Neuropathy Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AlgoTherapeutix
  • 18.7. Amgen Inc.
  • 18.8. Array BioPharma Inc. by Pfizer Inc.
  • 18.9. Artelo Biosciences, Inc.
  • 18.10. Asahi Kasei Corporation
  • 18.11. Astellas Pharma Inc.
  • 18.12. Bexion Pharmaceuticals, Inc.
  • 18.13. Bristol-Myers Squibb Company
  • 18.14. Eisai Inc.
  • 18.15. F. Hoffmann-La Roche Ltd
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Glenmark Pharmaceuticals Ltd.
  • 18.18. Grunenthal GmbH
  • 18.19. Heron Therapeutics, Inc.
  • 18.20. Ipsen Pharma
  • 18.21. Kyowa Kirin Co., Ltd.
  • 18.22. Merck & Co., Inc.
  • 18.23. Neuralace Medical
  • 18.24. Novartis AG
  • 18.25. Regenacy Pharmaceuticals LLC
  • 18.26. Regeneron Pharmaceuticals, Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Serpin Pharma, LLC
  • 18.29. Takeda Pharmaceutical Company Limited
  • 18.30. Veloxis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)